Polomar Health Services, Inc.
PMHS evidence brief
What we can confirm
- BioSniper Score:
- 2.9 / 10
- Market Cap:
- $5.7M
- Lead Asset:
- vigorair (Preclinical)
What it means
What to watch
Prepared research question
What matters most for PMHS—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · PMHS
Polomar Health Services, Inc. (PMHS) is an early-stage pharmacy and telehealth platform focused on compounded GLP-1 weight-loss medications, operating with a limited revenue base and significant going-concern risks.
Key risk: Going concern risk
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Market Cap
$5.7M
Cash Runway
—
Lead Asset
vigorair (Preclinical)
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 1 pipeline candidate for Polomar Health Services, Inc..
Polomar Health Services, Inc. (PMHS) is an early-stage pharmacy and telehealth platform focused on compounded GLP-1 weight-loss medications, operating with a limited revenue base and significant going-concern risks.
- Total revenue of $1.5M and net income of $0.2M for the six months ended June 30, 2026, with negative shareholders' equity of -$1.1M [sec].
- The company has a history of net losses, reporting a net loss of $10,701,105 for the period ended May 6, 2026, and an accumulated deficit of $1,921,040 as of June 30, 2024 [sec_mda · as of 2026-05-06][sec · filed 2024-10-04].
- Polomar acquired Polomar Pharmacy in September 2024, transitioning from a local dermatology pharmacy to a national prescription fulfillment platform for compounded GLP-1 medications [sec_mda · as of 2026-08-14].
- The company faces substantial doubt about its ability to continue as a going concern, with cash of only $3,026 as of the period ended in late 2025 [sec · filed 2025-12-05][sec · filed 2024-10-04].
- Polomar has licensed proprietary dry powder inhaler (DPI) technology from Pinata and plans to launch a weight-loss telehealth platform, SlimRx, in early 2026 [sec · filed 2025-12-05].
What works
- The company has secured a pharmacy services agreement with CareValidate, generating revenue through prescription fulfillment for telehealth patients [sec_mda · as of 2026-08-14].
- Polomar has obtained sterile compounding capabilities and expanded its prescription fulfillment services, positioning it in the growing compounded GLP-1 market [sec_mda · as of 2026-08-14].
- The company holds proprietary, patent-pending medication delivery technology (DPI) that may increase drug bioavailability, potentially offering a competitive edge [sec · filed 2025-12-05].
What to weigh
- Polomar has an unproven business plan and a history of net losses, with no assurance of achieving profitability [sec · filed 2024-10-04][sec · filed 2025-12-05].
- The company's cash position is critically low ($3,026 as of late 2025), and it has substantial doubt about its ability to continue as a going concern [sec · filed 2025-12-05][sec · filed 2024-10-04].
- Polomar faces significant patent infringement risks from major competitors (Eli Lilly and Novo Nordisk) regarding its compounded GLP-1 drugs, which could lead to costly litigation [sec · filed 2024-10-04].
- The company has insufficient access to capital to implement its business plan and relies on raising additional funds, which is not guaranteed [sec · filed 2025-12-05][sec_mda · as of 2026-05-06].
From the filings
Quoted directly from source documents.
Going concern uncertainty
“These factors raise substantial doubt about our ability to continue as a going concern.”
SEC filings · October 4, 2024
History of net losses
“We have a history of net losses and anticipate that we will continue to incur net losses for the foreseeable future.”
SEC filings · October 4, 2024
Patent infringement risk for GLP-1 drugs
“We dispense GLP-1 agonist drugs which include tirzepatide and semaglutide, these drugs are marketed by Eli Lilly and Company (Mounjaro and Zepbound) and Novo Nordisk (Ozempic and Wegovy), respectively.”
SEC filings · October 4, 2024
Transition to national fulfillment platform
“Since acquiring Polomar Pharmacy in September 2024, the Company has transitioned from a predominantly local dermatology-focused pharmacy to a national prescription fulfillment platform.”
SEC MD&A · August 14, 2026
Risks & what to watch (4)›
Key risks
- Going concern risk — Substantial doubt about ability to continue as a going concern due to losses and low cash [sec · filed 2024-10-04].
- Patent litigation risk — Compounded GLP-1 drugs may infringe on Eli Lilly and Novo Nordisk patents, leading to costly litigation [sec · filed 2024-10-04].
- Capital insufficiency — Insufficient access to capital to implement business plan; may need to scale back operations [sec_mda · as of 2026-05-06].
- Unproven business model — Early-stage company with no proven business plan and limited operating history [sec · filed 2025-12-05].
What to watch
- Launch of SlimRx weight-loss telehealth platform, planned for early 2026 [sec · filed 2025-12-05].
- Ability to raise additional capital to fund operations and address going-concern issues [sec_mda · as of 2026-05-06].
- Revenue growth from the CareValidate pharmacy services agreement and national fulfillment expansion [sec_mda · as of 2026-08-14].
- Outcome of any patent-related disputes with Eli Lilly or Novo Nordisk regarding compounded GLP-1 drugs [sec · filed 2024-10-04].
Sources: SEC filings · SEC MD&A · Generated September 24, 2026 · How we verify sources →
Run Polomar Health Services, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Polomar Health Services, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
Cash runway data unavailable
Net income $200K
Lead: Preclinical
1 candidate
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Financials
Governance
Frequently asked questions
What is the AI investment thesis for Polomar Health Services, Inc.?
Polomar Health Services, Inc. (PMHS) is an early-stage pharmacy and telehealth platform focused on compounded GLP-1 weight-loss medications, operating with a limited revenue base and significant going-concern risks.
What is Polomar Health Services, Inc.'s lead drug candidate?
Polomar Health Services, Inc.'s most advanced tracked candidate is vigorair (Preclinical) for erectile dysfunction.
Who is the CEO of Polomar Health Services, Inc.?
Mr. Terrence M. Tierney J.D. is the chief executive officer of Polomar Health Services, Inc. (PMHS).
Where is Polomar Health Services, Inc. headquartered?
Polomar Health Services, Inc. (PMHS) is headquartered in Los Angeles, CA, United States.
What therapeutic areas does Polomar Health Services, Inc. focus on?
Polomar Health Services, Inc. develops therapies across Reproductive.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.